NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem announces today that it approached the FDA regarding the cellular treatment it is developing for ALS. This is the initial approach the company is making to the FDA. In the framework of talks with the FDA, Kadimastem intends to consolidate a preliminary outline for its continuing trials for this indication.
Recently, the company reported positive results in a pre-clinical trial it conducted. In the trial, the efficacy of injecting support cells (astrocytes), produced by the company in a unique technology, into the spinal fluid of ALS model mice, was tested. This model is highly significant in predicting the treatment’s activity in humans.
Help employers find you! Check out all the jobs and post your resume.
